Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants

Medical Physics

Volumn 32, Issue 8, 2005, Pages 2557-2566

  Chibani, Omar ^a   Williamson, Jeffrey F ^a   Todor, Dorin ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANISOTROPY; LIGHT SCATTERING; PHOTONS; UROLOGY;

ATTENUATION EFFECT; DIFFERENT STRUCTURE; DOSE CONTRIBUTION; DOSE UNCERTAINTIES; MORPHOLOGICAL CHANGES; PROSTATE IMPLANTS; TISSUE HETEROGENEITY; TRANSRECTAL ULTRASOUND;

MONTE CARLO METHODS;

IODINE 125; PALLADIUM 103;

ANISOTROPY; ARTICLE; CALCULATION; CASE REPORT; DOSIMETRY; ELECTRON; HUMAN; IMPLANT; MODEL; MONTE CARLO METHOD; PHOTON; PRIORITY JOURNAL; PROSTATE; RADIATION DOSE DISTRIBUTION; RECTUM; URETHRA;

EID: 23944509702     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1897466     Document Type: Article

References (40)

1. H. H. Holm et al., "Transpireneal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography," J. Urol. (Baltimore) 130, 283-286 (1983).
2. P. L. Vijverberg, K. H. Kurth, L. E. Blank, N. F. Dabhoiwala, T. H. De Reijke, and K. Koedoor, "Treatment of localized prostatic carcinoma using the transrectal ultrasound guided transperineal implantation technique." Eur. Urol. 21, 35-41 (1992).
3. K. W. Kaye, D. J. Olson, and J. T. Payne, "Detailed preliminary analysis of 125 iodine implantation for localized prostate cancer using percutaneous approach," J. Urol. (Baltimore) 153, 1020-1025 (1995).
4. S. H. Stokes, J. D. Real, P. W. Adams, J. C. Clements, S. Wuertzer, and W. Can, "Transpireneal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate," Int. J. Radiat. Oncol., Biol., Phys. 37, 337-341 (1997).
5. H. Radge, J. C. Blasko, P. D. Grimm, G. M. Kenny, J. E. Sylvester, D. C. Hoak, K. Landin, and W. Cavanagh, "Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma," Cancer (N.Y.) 80, 442-453 (1997).
6. S. Nag, W. Bice, K. Dewingaert, B. Prestige, R. Stock, and Y. Yu, "The american brachytherapy society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis," Int. J. Radiat. Oncol., Biol., Phys. 46, 221-230 (2000).
7. G. S. Merrick, W. M. Butler, A. T Dorsey, and J. H. Lief, "Potential role of various dosimetric quality indicators in prostate brachytherapy," Int. J. Radiât. Oncol., Biol., Phys. 44, 717-724 (1999).
8. Y Yu, L. L. Anderson, Z. Li. D. E. Mellenberg, R. Nath, M. C. Schell, F. M. Waterman, A. Wu, and J. C. Blasko, "Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64." Med. Phys. 26, 2054-2076 (1999).
9. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Meigooni, "Dosimetry of interstitial brachytherapy sources: Recom-mendations of the AAPM Radiation Therapy Committee Task Group No. 43," Med. Phys. 22, 209-234 (1995).
10. A. S. Meigooni and R. Nath, "Tissue inhomogeneity correction for brachytherapy sources in a homogeneous phantom with cylindrical symmetry." Med. Phys. 19, 401-407 (1992).
11. G. M. Daskalov, A. S. Kirov, and J. F. Williamson, "Analytical approach to heterogeneity correction factor calculation for brachytherapy," Med. Phys. 25, 722-735 (1998).
12. A. S. Kirov, J. F. Williamson, A. S. Meigooni, and Y. Zhu, "Measurement and calculation of heterogeneity correction factors for an Ir-192 high dose-rate brachytherapy source behind tungsten alloy and steel shields," Med. Phys. 23, 911-919 (1996).
13. J. J. Demarco, J. B. Smathers, C. M. Burnison, Q. K. Ncube, and T. D. Solberg, "CT-based dosimetry calculations for 1251 prostate implants," Int. J. Radiat. Oncol., Biol., Phys. 45, 1347-1353 (1999).
14. G. S. Burns and D. E. Raeside, "The accuracy of single-seed dose super-position for 1-125 implants," Med. Phys. 16, 627-6632 (1989).
15. A. S. Meigooni, J. A. Meli, and R. Nath, "Interseed effects on dose for 1251 brachytherapy implants," Med. Phys. 19, 385-390 (1992).
16. 125I prostate implants," Phys. Med. Biol. 46, 2785-2800 (2001).
17. 103Pd," Med. Phys. 28, 336-345 (2001).
18. 125I seeds," Med. Phys. 15, 686-694 (1988).
19. 90Y and 192Ir SS sources for intravascular brachytherapy," Med. Phys. 27, 2528-2535 (2000).
20. J. G. Wierzbicki, M. J. Rivard, D. S. Waid, and V. E. Arterbery, "Calculated dosimetric parameters of the loGold 1251 source model 3631-A," Med. Phys. 25, 2197-2199 (1998).
21. O. Chibani and X. A. Li, "IVBTMC, A New General Dose Calculation Tool for Intravascular Brachytherapy," Med. Phys. 30, 44-54 (2003).
22. J. F Briesmeister, "MCNP General Monte Carlo N-Particle Transport," Los Alamos National Laboratory, Report, LA-12625 (2004).
23. M. J. Rivard, "Monte Carlo calculations of AAPM Task Group Report No. 43 dosimetry parameters for the MED3631-A/M 1251 source," Med. Phys. 28, 629-637 (2001).
24. B. Reniers, S. Vymckier, and P. Scalliet, "Dosimetric study of the new Intersource 1251 iodine seed," Med. Phys. 28, 2285-2288 (2001).
25. 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code," Med. Phys. 30, 701-710 (2003).
26. O. Chibani and X. A. Li, "Monte Carlo dose calculations in homogeneous media and at interfaces: A comparison between GEPTS, EGSnrc, MCNP and measurements," Med. Phys. 29, 835-847 (2002).
27. Y. Watanabe, J. Roy, P. J. Harrington, and L. L. Anderson, "Experimental and Monte Carlo dosimetry of the Henschke applicator for high dose-rate 192Ir remote afterloading," Med. Phys. 25, 736-745 (1998).
28. R. Wang and X. A. Li, "Monte Carlo dose calculations of beta-emitting for intravascular brachytherapy: A comparison between EGS4, EGSnrc, and MCNP," Med. Phys. 28, 134-141 (2001).
29. O. Chibani and X. A. Li, "Dosimetric effects of source-offset in intravascular brachytherapy," Med. Phys. 29, 530-537 (2002).
30. J. H. Hubbel, W. J. Veigele, E. A. Briggs, R. T. Brown, D. T. Cromer, and R. J. Howerton, "Atomic Form factors, incoherent scattering functions and photon scattering cross sections," J. Phys. Chem. Ref. Data 4, 471-538 (1975).
31. J. H. Hubbel and I. OØverbo. "Relativistic atomic form factors and photon coherent cross sections," J. Phys. Chem. Ref. Data 8, 69-105 (1979).
32. D. E. Cullen, J. H. Hubbel, and L. Kissel, "ENDLIB-97: LLNL librairies of atomic data, electron data and photon data in evaluated nuclear data library (ENDL) type format," Radiation Safety Information Computational Center, Data Library DLC-179, Oak Ridge National Laboratory, TN, (1997).
33. C. J. Everett and E. D. Cashwell, "MCP Code Fluoresence-Routine Revision," Report LA-5240-MS, Los Alamos National Laboratory (1973).
34. H. Hedtjarn, G. A. Carlson, and J. F. Williamson, "Accelerated Monte Carlo based dose calculations for brachytherapy planning using correlated sampling," Phys. Med. Biol. 47, 351-376 (2002).
35. 103Pd interstitial brachytherapy source," Med. Phys. 27, 643-654 (2000).
36. 125I, interstitial brachytherapy seed," Med. Phys. 27, 1076-1085 (2000).
37. 103Pd interstitial brachytherapy seed," Med. Phys. 29, 609-621 (2002).
38. J. J. Demarco, T. D. Solberg, and J. B. Smathers, "CT-based Monte Carlo simulation tool for dosimetry planning and analysis," Med. Phys. 25, 1-11 (1998).
39. D. A. Todor, M. Zaider, G. N. Cohen, M. F. Worman, and M. J. Zelefsky, "Intraoperative dynamic dosimetry for prostate implants," Phys. Med. Biol. 48, 1153-1171 (2003).
40. P Mobit and I. Badragan, "Dose perturbation effects in prostate seed implant brachytherapy with 1-125," Phys. Med. Biol. 49, 3171-3178 (2004).